CapEdge
Loading...
Advanced
What's new? Log in Free sign up
  • Home
  • Sectors & IndustriesSectors
  • Earnings
  • IPOs
  • SPACs
  • Transcripts
  • Insider
  • Institutional
  • Crypto
  • Screeners
  • Reddit
  • Splits
  • AMYT Dashboard
  • Financials
  • Filings
  • Transcripts
  • ETFs
  • Shorts
  • News
  • Reddit
  • 6-K Filing

Amryt Pharma (AMYT) 6-KFDA Grants Priority Review for New Drug Application for Oleogel-S10 for the Treatment of Epidermolysis Bullosa

Filed: 3 Jun 21, 6:03am
Free signup for more
  • Track your favorite companies
  • Receive email alerts for new filings
  • Personalized dashboard of news and more
  • Access all data and search results
Sign up for free
Search this filing
?
Pre-defined:
Table of contents
    Filing tables
    Export all tables to Excel
    Filing exhibits
    SEC
    • 6-K Current report (foreign)
    • 99.1 FDA Grants Priority Review for New Drug Application for Oleogel-S10 for the Treatment of Epidermolysis Bullosa
    AMYT similar filings
    • 28 Jul 21 Result of General Meetings
    • 28 Jun 21 Current report (foreign)
    • 7 Jun 21 FDA confirms NDA for Oleogel-S10 will not require an Advisory Committee Meeting
    • 3 Jun 21 FDA Grants Priority Review for New Drug Application for Oleogel-S10 for the Treatment of Epidermolysis Bullosa
    • 2 Jun 21 Amryt Announces FDA Acceptance of New Drug Application for Oleogel-S10 for the Treatment of Epidermolysis Bullosa
    • 5 May 21 Agreement and Plan of Merger
    • 5 May 21 Amryt Reports Record Q1 2021 Financial and Operating Results
    Filing view
    Share this filing
     

    UNITED STATES
    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549

    Form 6-K

    Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16
    under the Securities Exchange Act of 1934

    For the month of June 2021

    Commission File Number: 001-39365

    Amryt Pharma plc
    (Translation of registrant's name into English)

    Dept 920a 196 High Road, Wood Green,
    London, United Kingdom, N22 8HH

    (Address of principal executive office)

    Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.
    Form 20-F [ X ]      Form 40-F [   ]

    Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1):       

    Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7):       


    EXHIBIT INDEX 

    Exhibit Number Description
       
    99.1 Exhibit 99.1


    SIGNATURES

    Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

          Amryt Pharma plc    
      (Registrant)
       
      
    Date: June 3, 2021     /s/ Rory Nealon    
      Rory Nealon
      Chief Financial Officer
      
    Finsight
    Resources
    • Knowledgebase
    • Log In
    • Register
    Company
    • About
    • Contact
    • Solutions
    Products
    • Deal Roadshow
    • DealVDR
    • Evercall
    • Finsight.com
    CapEdge
    • Earnings Calendar
    • Earnings Transcripts
    • EDGAR Filing Screener
    • IPO Calendar
    • Compliance
    • Privacy
    • Security
    • Terms
    AngelList LinkedIn